Featured Articles

AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier…
Read More...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) approved the indication extension for DARZALEX (daratumumab) subcutaneous…
Read More...

Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous…
Read More...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise…
Read More...

Exelixis, Inc. and Merck, known as MSD outside of the United States and Canada, announced that the companies have entered into a clinical development collaboration to evaluate the…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with unresectable,…
Read More...

UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing…
Read More...

Roche announced that the United States Food and Drug Administration (FDA) approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of…
Read More...

Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that…
Read More...

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a dual glucagon/GLP-1 receptor…
Read More...

Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, announced that they have entered…
Read More...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo  (nivolumab) for the treatment of adult patients with resectable (tumors ≥4 cm or node…
Read More...

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the…
Read More...

AstraZeneca’s Tagrisso (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm)…
Read More...

Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare,…
Read More...

Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced U.S. Food and Drug Administration (FDA) approval of BORUZU, a new presentation of bortezomib for ready-to-use…
Read More...

Evotec SE and X-Chem, leader in DNA-encoded library (DEL) technology, announced a collaboration agreement focused on accelerating early-stage drug discovery. X-Chem’s DEL technology …
Read More...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination…
Read More...